Detection of prostate cancer at low and intermediate serum prostate-specific antigen levels in a country with a low incidence of prostate cancer

Sang Eun Lee, Seok-Soo Byun, Hyoung Keun Park, Hong Bang Shim, Ja Hyeon Ku

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The objective of this study was to evaluate the cancer detection rate and the pathologic findings of biopsy in men at low and intermediate prostate-specific antigen (PSA) levels in an Asian population. Methods: Patients between 40 and 79 years were entered into a study and 755 patients with serum PSA level of 2.0-10.0 ng/ml underwent trus-guided systematic biopsy. Patients were divided to low (PSA 2.0-4.0 ng/ml, n = 144) and intermediate (PSA 4.1-10.0 ng/ml, n = 611) PSA groups. Results: Patients in the low PSA group had significantly smaller prostates (P = 0.003) and lower PSA density (P < 0.001). The rate of cancer detection was 16.7% (24 of 144) in the low PSA group and 23.7% (145 of 611) in the intermediate PSA group (P = 0.067). In men with normal digital rectal examination (DRE), prostate cancer was diagnosed in 14 (13.3%) of the 105 men in the low PSA group and 99 (19.5%) of the 508 men in the intermediate PSA group (P = 0.139). In all patients and patients with normal DRE, no statistically significant differences were found in the pathologic findings of biopsy between the two groups. Conclusions: Our findings provide a rationale to recommend prostate biopsy at lower PSA threshold in this population. At present, however, it is not clear that men who are treated when their cancers are detected at lower PSA levels have better outcomes than those who are treated when the PSA is higher than 4.0 ng/ml.

Original languageEnglish
Pages (from-to)376-380
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume36
Issue number6
DOIs
StatePublished - 1 Jun 2006

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Incidence
Serum
Biopsy
Digital Rectal Examination
Prostate
Neoplasms
Population

Keywords

  • Asian
  • Prostate cancer
  • Prostate neoplasms
  • Prostate-specific antigen

Cite this

@article{08b62475d59a49c98899a2fa99f9cd1b,
title = "Detection of prostate cancer at low and intermediate serum prostate-specific antigen levels in a country with a low incidence of prostate cancer",
abstract = "Background: The objective of this study was to evaluate the cancer detection rate and the pathologic findings of biopsy in men at low and intermediate prostate-specific antigen (PSA) levels in an Asian population. Methods: Patients between 40 and 79 years were entered into a study and 755 patients with serum PSA level of 2.0-10.0 ng/ml underwent trus-guided systematic biopsy. Patients were divided to low (PSA 2.0-4.0 ng/ml, n = 144) and intermediate (PSA 4.1-10.0 ng/ml, n = 611) PSA groups. Results: Patients in the low PSA group had significantly smaller prostates (P = 0.003) and lower PSA density (P < 0.001). The rate of cancer detection was 16.7{\%} (24 of 144) in the low PSA group and 23.7{\%} (145 of 611) in the intermediate PSA group (P = 0.067). In men with normal digital rectal examination (DRE), prostate cancer was diagnosed in 14 (13.3{\%}) of the 105 men in the low PSA group and 99 (19.5{\%}) of the 508 men in the intermediate PSA group (P = 0.139). In all patients and patients with normal DRE, no statistically significant differences were found in the pathologic findings of biopsy between the two groups. Conclusions: Our findings provide a rationale to recommend prostate biopsy at lower PSA threshold in this population. At present, however, it is not clear that men who are treated when their cancers are detected at lower PSA levels have better outcomes than those who are treated when the PSA is higher than 4.0 ng/ml.",
keywords = "Asian, Prostate cancer, Prostate neoplasms, Prostate-specific antigen",
author = "Lee, {Sang Eun} and Seok-Soo Byun and Park, {Hyoung Keun} and Shim, {Hong Bang} and Ku, {Ja Hyeon}",
year = "2006",
month = "6",
day = "1",
doi = "10.1093/jjco/hyl032",
language = "English",
volume = "36",
pages = "376--380",
journal = "Japanese journal of clinical oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "6",

}

Detection of prostate cancer at low and intermediate serum prostate-specific antigen levels in a country with a low incidence of prostate cancer. / Lee, Sang Eun; Byun, Seok-Soo; Park, Hyoung Keun; Shim, Hong Bang; Ku, Ja Hyeon.

In: Japanese Journal of Clinical Oncology, Vol. 36, No. 6, 01.06.2006, p. 376-380.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Detection of prostate cancer at low and intermediate serum prostate-specific antigen levels in a country with a low incidence of prostate cancer

AU - Lee, Sang Eun

AU - Byun, Seok-Soo

AU - Park, Hyoung Keun

AU - Shim, Hong Bang

AU - Ku, Ja Hyeon

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Background: The objective of this study was to evaluate the cancer detection rate and the pathologic findings of biopsy in men at low and intermediate prostate-specific antigen (PSA) levels in an Asian population. Methods: Patients between 40 and 79 years were entered into a study and 755 patients with serum PSA level of 2.0-10.0 ng/ml underwent trus-guided systematic biopsy. Patients were divided to low (PSA 2.0-4.0 ng/ml, n = 144) and intermediate (PSA 4.1-10.0 ng/ml, n = 611) PSA groups. Results: Patients in the low PSA group had significantly smaller prostates (P = 0.003) and lower PSA density (P < 0.001). The rate of cancer detection was 16.7% (24 of 144) in the low PSA group and 23.7% (145 of 611) in the intermediate PSA group (P = 0.067). In men with normal digital rectal examination (DRE), prostate cancer was diagnosed in 14 (13.3%) of the 105 men in the low PSA group and 99 (19.5%) of the 508 men in the intermediate PSA group (P = 0.139). In all patients and patients with normal DRE, no statistically significant differences were found in the pathologic findings of biopsy between the two groups. Conclusions: Our findings provide a rationale to recommend prostate biopsy at lower PSA threshold in this population. At present, however, it is not clear that men who are treated when their cancers are detected at lower PSA levels have better outcomes than those who are treated when the PSA is higher than 4.0 ng/ml.

AB - Background: The objective of this study was to evaluate the cancer detection rate and the pathologic findings of biopsy in men at low and intermediate prostate-specific antigen (PSA) levels in an Asian population. Methods: Patients between 40 and 79 years were entered into a study and 755 patients with serum PSA level of 2.0-10.0 ng/ml underwent trus-guided systematic biopsy. Patients were divided to low (PSA 2.0-4.0 ng/ml, n = 144) and intermediate (PSA 4.1-10.0 ng/ml, n = 611) PSA groups. Results: Patients in the low PSA group had significantly smaller prostates (P = 0.003) and lower PSA density (P < 0.001). The rate of cancer detection was 16.7% (24 of 144) in the low PSA group and 23.7% (145 of 611) in the intermediate PSA group (P = 0.067). In men with normal digital rectal examination (DRE), prostate cancer was diagnosed in 14 (13.3%) of the 105 men in the low PSA group and 99 (19.5%) of the 508 men in the intermediate PSA group (P = 0.139). In all patients and patients with normal DRE, no statistically significant differences were found in the pathologic findings of biopsy between the two groups. Conclusions: Our findings provide a rationale to recommend prostate biopsy at lower PSA threshold in this population. At present, however, it is not clear that men who are treated when their cancers are detected at lower PSA levels have better outcomes than those who are treated when the PSA is higher than 4.0 ng/ml.

KW - Asian

KW - Prostate cancer

KW - Prostate neoplasms

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=33745900748&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyl032

DO - 10.1093/jjco/hyl032

M3 - Article

C2 - 16735369

AN - SCOPUS:33745900748

VL - 36

SP - 376

EP - 380

JO - Japanese journal of clinical oncology

JF - Japanese journal of clinical oncology

SN - 0368-2811

IS - 6

ER -